- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT07943728
Yangyin Qingfei Decoction for Radiation Pneumonitis Prevention (YARD-01)
A Prospective Phase II Clinical Study to Evaluate the Efficacy and Safety of Yangyin Qingfei Decoction in Preventing Radiation Pneumonitis
This prospective, randomized, controlled, open-label phase II clinical study will enroll patients with thoracic malignancies who are scheduled to receive thoracic radiotherapy and whose baseline chest CT/high-resolution CT (HRCT) shows no active pulmonary disease or prior radiation-induced lung injury that could interfere with the assessment of radiation pneumonitis (RP). Eligible patients will be randomized 1:1 to a treatment group or a control group. The control group will receive standard thoracic radiotherapy and routine supportive care; the treatment group will additionally receive oral Yangyin Qingfei Formula concurrently. Patients will be followed for 12 months after radiotherapy to evaluate the formula's efficacy, safety, and potential clinical translational value in preventing RP.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Studientyp
Einschreibung (Geschätzt)
Phase
- Phase 2
Kontakte und Standorte
Studienkontakt
- Name: Yujie Hu, MD
- Telefonnummer: 18368101682
- E-Mail: huyujie@zjhtcm.com
Studienorte
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310000
- Department of Radiotherapy, The First Affiliated Hospital of Zhejiang Chinese Medical University
-
Kontakt:
- chao chen, MD
- Telefonnummer: 13805788140
- E-Mail: 20053006@zcmu.edu.cn
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion criteria
- Age 18-80 years.
- A pathologically or cytologically confirmed thoracic malignancy, including lung cancer, esophageal cancer, thymic tumors, or similar tumors.
- Planned thoracic radiotherapy, with lung tissue expected to lie within the radiation field.
- No active pulmonary disease or prior radiation-induced lung injury on baseline chest CT/HRCT that could interfere with RP assessment.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
- Estimated survival of at least 6 months.
- Blood counts: absolute neutrophil count >=3.0 x 10^9/L, platelets >=100 x 10^9/L, and hemoglobin >=90 g/L.
- Biochemistry: total bilirubin, blood urea nitrogen, and creatinine <=1.5 times the upper limit of normal (ULN); alanine aminotransferase and aspartate aminotransferase <=2 times the ULN.
- Ability to eat normally and take a Chinese herbal decoction; voluntary participation and written informed consent.
Exclusion criteria
- Baseline chest CT/HRCT showing active pulmonary infection, interstitial lung disease, marked pulmonary fibrosis, immunotherapy-related pneumonitis, tumor-related post-obstructive pneumonia, or another pulmonary condition that could interfere with RP assessment.
- Unequivocal tumor progression according to RECIST 1.1, or an investigator's judgment that radiotherapy and follow-up cannot be completed in the near term.
- Severe hepatic, renal, cardiovascular, gastrointestinal, or metabolic disease that could affect the safety or efficacy assessment of the study treatment.
- Pregnancy or breastfeeding, or a severe psychiatric disorder that prevents cooperation with the study.
- Participation in another interventional clinical trial within the previous 3 months.
- Regular use of other Chinese herbal medicines, Chinese patent medicines, or antifibrotic drugs specifically intended to prevent RP.
- Poor adherence, inability to take the herbal decoction regularly, or inability to complete scheduled follow-up.
- Any other condition judged by the investigator to make the patient unsuitable for enrollment.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Verhütung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Yangyin Qingfei Formula plus standard thoracic radiotherapy and routine supportive care
|
Yangyin Qingfei decoction will contain Tai Zi Shen (Pseudostellariae Radix) 15 g, Mai Dong (Ophiopogonis Radix) 15 g, Tian Dong (Asparagi Radix) 15 g, Nan Sha Shen (Adenophorae Radix) 15 g, Bei Sha Shen (Glehniae Radix) 15 g, Huang Qin (Scutellariae Radix) 15 g, and Jiao Shan Zhi (charred Gardeniae Fructus) 9 g. One daily prescription will be administered in two doses, 200 mL per dose. If grade 1 gastrointestinal discomfort or another adverse reaction judged possibly related to the decoction occurs, the dose may be reduced to 100 mL twice daily and restored to 200 mL twice daily after symptoms resolve. For grade 2 adverse reactions, the decoction may be suspended and symptomatic treatment provided; after recovery to grade 0-1, treatment may be resumed, with or without dose reduction, at the investigator's discretion. If a grade >=3 adverse reaction, a serious adverse event, or clinically significant decoction-related intolerance occurs, decoction treatment should be stopped, with the r |
|
Aktiver Komparator: Standard thoracic radiotherapy plus routine supportive care
Standard thoracic radiotherapy plus routine supportive care |
The control group will receive standard thoracic radiotherapy and routine supportive care without Yangyin Qingfei decoction. Supportive care includes nutritional support and symptomatic management, such as cough relief, expectoration, relief of wheezing, and anti-infective treatment when necessary. Chemotherapy, targeted therapy, or immunotherapy may be administered during follow-up at the investigator's discretion, under the same principles as in the treatment group. Prophylactic amifostine, nintedanib, or other antifibrotic drugs will not be used routinely, nor will other Chinese herbal medicines, Chinese patent medicines, or health supplements specifically intended to prevent RP be used. |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
|---|---|
|
Incidence of grade >=2 RP
Zeitfenster: 3 months after radiotherapy completion
|
3 months after radiotherapy completion
|
Mitarbeiter und Ermittler
Ermittler
- Hauptermittler: chao chen, MD, The First Affiliated Hospital of Zhejiang Chinese Medical University
Publikationen und hilfreiche Links
Allgemeine Veröffentlichungen
- Giuranno L, Ient J, De Ruysscher D, Vooijs MA. Radiation-Induced Lung Injury (RILI). Front Oncol. 2019 Sep 6;9:877. doi: 10.3389/fonc.2019.00877. eCollection 2019.
- Hou Z, Dong B, Yao Q, Chen H, Shao Q, Li M, Wang J, Chen K, Zhu Z, Peng F, Wei S, Hu X, Li J, Liu M, Xu B, Zheng S, Bi N, Zheng S, Xu Q, Chen B, Wu C, Li R, Chen W, Liu X, Tian Y, Li X, Guo S, Zhao L, Zhu Y, Cai L, Li Q, Li L, Zhang H, Hu C, Wang L, Li Q, Chen B, Chen M. Pirfenidone for grade 2 and grade 3 radiation-induced lung injury: a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol. 2025 Dec;26(12):1552-1562. doi: 10.1016/S1470-2045(25)00515-7. Epub 2025 Nov 6.
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Geschätzt)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- 2027-KS-133-01
- 2027117845 (Andere Zuschuss-/Finanzierungsnummer: 2027 Annual Zhejiang Provincial Traditional Chinese Medicine Science and Technology Program)
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
De-identified individual participant data will not be publicly released. Data may be available from the principal investigator upon reasonable request with a formal data-use agreement
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .